Monday, 25 March 2019

Ajinomoto and XL-protein unite to develop therapeutic compounds

19 December 2018 | News

Ajinomoto will apply its proprietary Corynex® expression system together with XL-protein's proprietary PASylation® technology for plasma half-life extension to develop a series of therapeutic compounds.

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan and India. 

Ajinomoto Bio-Pharma pleased to announce a Strategic alliance with XL-protein GmbH, a privately owned German biopharmaceutical company. Ajinomoto will apply its proprietary Corynex® expression system together with XL-protein's proprietary PASylation® technology for plasma half-life extension to develop a series of therapeutic compounds.

Ajinomoto and XL-protein have established the efficient production of a PASylated proprietary GLP-1 variant with an extended half-life at laboratory scale yielding >3 grams soluble protein per liter bacterial culture including facile purification from the supernatant.

The PASylated GLP-1 variant maintains high receptor affinity. In vivo pharmacokinetic studies in mice have revealed a drastically prolonged half-life, suggesting potentially weekly or biweekly dosing in human patients. Ajinomoto has started a partnering process for this molecule.

Financial terms of the agreement have not been disclosed.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Can collaboration between startups and big life sciences companies offer a disruptive breakthrough?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls